NCT05830097 2024-08-26
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Coherent Biopharma (Hefei) Co., Ltd.
Phase 1/2 Unknown
Clinical Trials
12 trialsNCT05711030 2024-02-20
TPVB
Ciusss de L'Est de l'Île de Montréal
Phase NA Unknown
NCT05755048 2023-09-01
FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3 Unknown
NCT05845138 2023-08-01
A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Unknown
NCT05753865 2023-03-03
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT05560308 2022-10-03
Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT04405505 2020-05-28
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT04213898 2019-12-30
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Henan Cancer Hospital
Phase 1/2 Unknown
NCT04185649 2019-12-04
The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Bio-Thera Solutions
Phase 3 Unknown
NCT03024580 2019-08-15
MEGA
Instituto Nacional de Cancer, Brazil
Phase 2 Unknown
NCT02953184 2017-12-29
Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy
Jilin University
Phase 2 Unknown
NCT01428414 2012-08-23
Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer
Fudan University
Phase 2 Unknown